7,580.07

-140.32

-1.82%

51,770.31

-572.25

-1.09%

25,437.00

-747.73

-2.86%

2,811.84

-47.37

-1.66%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,898.90

-132.50

-3.29%

77,643.56

+632.34

+0.82%

Crude Oil Dec 26

104.12

+2.12

+2.08%

US Private Equity

10,850.63

-82.20

-0.75%

Hamburg - Delayed Quote EUR

Bristol-Myers Squibb Co (BRM.HM)

56.15 +1.91 (+3.52%)

At close: October 30 at 5:25:02 PM GMT+1

Loading Chart for BRM.HM

Chart Range Bar

Interval:

In partnership with ChartIQ

Bristol Myers Squibb (BMY) Reports Positive Phase 2 Pumitamig Lung Cancer Data

Bristol Myers Squibb (BMY) Reports Positive Phase 2 Pumitamig Lung Cancer Data

AstraZeneca Has an $80 Billion Dream and a Plan to Fix Its Stalling Stock

AstraZeneca Has an $80 Billion Dream and a Plan to Fix Its Stalling Stock

BMY Q3 Earnings Call Highlights Raised Outlook and Pipeline Progress

BMY Q3 Earnings Call Highlights Raised Outlook and Pipeline Progress

Pfizer Yields Nearly 6%, but Its Dividend Exceeds Free Cash Flow. Is It Safe?

Pfizer Yields Nearly 6%, but Its Dividend Exceeds Free Cash Flow. Is It Safe?

Is 50% Crash Risk For Iovance Stock Real?

Is 50% Crash Risk For Iovance Stock Real?

Eli Lilly’s tirzepatide outperforms big pharma companies in Q3

Eli Lilly’s tirzepatide outperforms big pharma companies in Q3

Company News for Oct 30, 2026

Company News for Oct 30, 2026

Bristol Myers Squibb Q3 Earnings Call Highlights

Bristol Myers Squibb Q3 Earnings Call Highlights

What Exelixis (EXEL) Said on Its Q3 Earnings Call

What Exelixis (EXEL) Said on Its Q3 Earnings Call

AI CRM Adoption Could Be A Key Catalyst For Veeva Systems Stock (VEEV)

AI CRM Adoption Could Be A Key Catalyst For Veeva Systems Stock (VEEV)

Bristol Myers’ Growth Drugs Hit $7.7 Billion: Rapid Earnings Reaction

Bristol Myers’ Growth Drugs Hit $7.7 Billion: Rapid Earnings Reaction

Mobilize your Website

View Site in Mobile | Classic

Share by: